Insight

Elisabetta Bonzano Highlighted ESTRO CNS Focus Group Study on Neuroprotection in Brain Metastases Care

Elisabetta Bonzano/X

Aug 12, 2025, 07:53

Elisabetta Bonzano Highlighted ESTRO CNS Focus Group Study on Neuroprotection in Brain Metastases Care

Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X about a recent paper by Nils Gleim et al., published in Radiotherapy and Oncology:

“Neuroprotection in radiotherapy of brain metastases – a European pattern-of-care analysis by the ESTRO CNS Focus group

The survey was completed by 234 ROs from 31 countries.
WBRT is the preferred treatment modality over SRT for 4–5 BM for 18 % and for 6–10 BM for 53 % of ROs.
HS-WBRT is generally offered by most ROs (85 %), only a minority apply the technique regularly (25 %), and prescription parameters vary considerably.
Concomitant memantine is prescribed by 30 % of ROs.
Boost treatments as part of WBRT are rarely performed on a regular basis (22 %)”

Elisabetta Bonzano

Title: Neuroprotection in radiotherapy of brain metastases – a European pattern-of-care analysis by the ESTRO CNS Focus group

Journal: Radiotherapy and Oncology

Authors: N. Gleim, A. Turcas, G. Minniti, A.L. Grosu, T. Kazda, M. Harat, S. Fernandez, M. Niyazi, N.H. Nicolay, C. Seidel

Read the full article.

Elisabetta Bonzano

More posts featuring Elisabetta Bonzano on OncoDaily.

A. Turcas A.L. Grosu C. Seidel cancer Elisabetta Bonzano G. Minniti IRCCS San Matteo Polyclinic Foundation M. Harat M. Niyazi N. Gleim N.H. Nicolay Nils Gleim OncoDaily Oncology S. Fernandez T. Kazda

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Ramy Sedhom: Palliative Care Isn’t Just about When. It’s about Who, What, and How

Miriam Mutebi: One Small Grant, One Big Difference

Jasmine Kamboj: How We Bring Ourselves to the Table as Leaders